Welcome to the Anticoagulation Therapy for Stroke Prevention Learning Zone, which introduces the intimate relationship between stroke and atrial fibrillation (AF). Warfarin reduces stroke risk in AF patients, but commonly causes major bleeds and other side effects. The need for regular monitoring and the risk of interactions often makes warfarin difficult to use clinically. Oral non-vitamin K antagonists transformed anticoagulant therapy for non-valvular AF offering improved efficacy and tolerability compared with warfarin.
Learn more about the treating patients with atrial fibrillation who present with ACS and/or require PCI and the AUGUSTUS trial in 2 interactive learning modules
Learn about the management options for atrial fibrillation using invasive treatment and anticoagulants
Find out what the European and American guidelines advise for managing your patients with atrial fibrillation
This Learning Zone reviews the epidemiology, pathophysiology, diagnosis and management of atrial fibrillation, including the latest anticoagulant guidelines, to help you balance the risks and benefits of the various invasive and pharmacological options. The Learning Zone helps you deliver optimal care and prevent strokes in your patients living with common sustained cardiac arrhythmia.
Alternatively login via
Back to epgonline.org